Therefore, we decided to test the above mentioned
compounds against two commonly used human HCC cell
lines: Huh-7 and HepG2.13 Cytotoxicity was assessed by
methyl-thiazolyl tetrazolium bromide (MTT) quantitative
derivative firstly obtained nearly 4 decades ago. With this
starting material, we synthesized a set of structurally related
compounds in only one simple step with very good yields
and some of them showed a very interesting activity against
two HCC cell lines. We also noted the key role exerted by
the carbonyl group in the biological activity. Finally, this
report shows a new horizon in the field of levoglucosenone´s
chemistry, allowing the synthesis of a novel class of
bioactive compounds with original structural features.
colorimetric assay, as described.14 In
a
preliminary
were active but
bearing an aromatic ring at C-4 showed
cytotoxicity. In contrast, compounds showed no
screening, we found that compounds
1 and 2
also derivatives
3-5
6-9
apparent cytotoxicity. Based on this outcome, the IC50
values for compounds 1-5 were determined after 48 h of
incubation with cells. The results of these assays are
summarized in Table 2.
Acknowledgments
Table 2
This research was supported by Agencia Nacional de Promoción
Científica y Tecnológica, CONICET and UNR from Argentina.
G. F. G. thanks ANPCyT and CONICET for the award of the
fellowships.
Cytotoxic assays against hepatocarcinoma cell lines
*
IC ( M)
50
Entry
Compound
Huh-7
12.94
4.68
11.02
12.79
8.79
HepG2
39.39
13.96
17.00
27.53
22.20
12.0
1
2
3
4
5
6
7
1
2
3
Supplementary Data
4
5N
Supplementary data (cytotoxic activity graphics, experimental
procedures and spectroscopic characterizations data of the
compounds) associated with this article can be found, in the
online version.
Sorafenib15a
11.3
Cisplatin15b
Doxorubicin15b
5-FU15b
3.09
7.28
0.68
8
9
0.24
390.00
205.19
References and notes
*See graphics in supplementary data
1. a) Corne, V.; Botta, M. C.; Giordano, E. D. V.; Giri, G. F.; Llompart,
D. F.; Biava, H. D.; Sarotti, A. M.; Mangione, M. I.; Mata, E. G.;
Suárez, A. G.; Spanevello, R. A. Pure Appl. Chem. 2013, 85, 1683; b)
Sarotti, A. M.; Zanardi, M. M.; Spanevello, R. A.; Suárez, A. G. Curr.
Org. Synth. 2012, 9, 439 and references therein cited.
2. Halpern, J.; Riffer, R.; Broido, A. J. Org. Chem. 1973, 38, 204.
3. Müller, C.; Gómez-Zurita Frau, M. A.; Ballinari, D.; Colombo, S.;
Bitto, A.; Martegani, E.; Airoldi, C.; van Neuren, A. S.; Stein, M.;
Weiser, J.; Battistini, C.; Peri, F. Chem. Med. Chem. 2009, 4, 524.
4. Nishi, Y.; Miyakawa, Y.; Kato, K.; Mutat. Res. 1989, 227, 117.
5. Giri G. F. Ph.D. Thesis, Universidad Nacional de Rosario, August
2015.
6. a) Sarotti, A. M.; Spanevello, R. A.; Suárez, A. G. Green Chem. 2007,
9, 1137. b) Morin, C. In Levoglucosenone and Levoglucosans:
Chemistry and Applications; Witczak, Z. J., Ed.; ATL Press, Mount
Prospect, 1994. Chapter 2.
7. Ward, D.; Shafizadeh, F. Carbohydr. Res. 1981, 93, 284.
8. Becker, B.; Thimm, J.; Thiem, J. J. Carbohydr. Chem. 1996, 15, 1179.
9. General Procedure for the conjugated addition: Levoglucosenone was
dissolved in anhydrous chloroform (5.5 mL) under Ar atmosphere,
followed by the sequential addition of the corresponding nucleophile
and base. The reaction was stirred at room temperature until the TLC
showed complete consumption of the Michael acceptor. Solvent was
evaporated under reduced pressure. The crude product obtained was
purified by column chromatography.
10. General Procedure for reduction: Ketones 4 and 6 were dissolved in
MeOH and NaBH4 98% was then added. The reaction was stirred at
room temperature until the TLC showed complete consumption of the
substrate. Acetone (0.5 mL) was then added and the mixture was
filtered through a celite pad. Solvent was evaporated under reduced
pressure. The crude product was purified by column chromatography
to separate the epimeric alcohols.
11. a) Xie, J-G.; Quan, J.; Li, S-B.; Zheng, Y.; Zhu, L-M. Synth. Commun.,
2011, 41, 871. b) Melzig, L.; Metzger, A.; Knochel, P. Chem. Eur. J.,
2011, 17, 2948. c) Kamat, M. N.; Nigam P.; Rath, N. P.; Demchenko,
A. V. J. Org. Chem. 2007, 72, 6938.
Table 2 showed that the activity of the new synthetic
derivatives was better than the one observed with
Compounds and 5N were even more active than Sorafenib
1.
2
and the first one was also comparable in activity with
Cisplatin (entry 2 with Huh-7 cell line),15 two of the drugs
clinically used nowadays to treat HCC. Another observation
derived from these experiments was that the Huh-7 cell line
resulted to be more susceptible to the in vitro therapy than
HepG2 cell line. Although the reason for this effect is still
unknown, it might be related to the fact that Huh-7 cells
possess a mutation in the p53 tumor suppressor gene while
HepG2 cells, conversely, has a normal p53. Interestingly,
mutations of the p53 tumor suppressor are present in the
majority of tumors, including HCC.16
Meanwhile, during the development of this research, a new
report in literature showed that some thio-sugars derivates
obtained from Michael type additions to
1 were active
against some tumoral cell lines, although the activities were
relatively low.17 The authors mentioned the relevance of C-
S-C bond angle in activity determination. In our examples
this assumption could be true for compounds
3 and 4 but in
the case of compound 5-N which has a C-N bond it could
not be applied. On the other hand, aliphatic analogs
which possess a C-S-C bond similar to and
6
4
and
were
7
3
inactive. A similar lost of activity was observed when the
carbonyl group was reduced to the corresponding alcohols
and . Based on the data collected with this small library of
8
9
12. Stotz, M.; Gerger, A.; Haybaeck, J.; Kiesslich, T.; Bullock, M. D.;
Pichler, M.; Anticancer Res. 2015, 35, 5737.
13. Krelle, A. C., Okoli, A. S. Mendz, G. L., J. Cancer Therapy, 2013, 4,
606.
compounds we could infer that in our case, the two main
features that were essential for the observed cytotoxic effect
were the aromatic moiety and the carbonyl group.
14. Marchissio, M. J.; Francés, D. E. A.; Carnovale, C. E.; Marinelli, R. A.
Toxicol. Appl. Pharmacol. 2012, 264, 246.
15. a) Cervello, M.; Bachvarov, D.; Lampiasi, N.; Cusimano, A.; Azzolina,
A.; McCubrey, J. A.; Montalto, G. Cell Cycle, 2012, 11, 2843. b)
Brito, A. F.; Abrantes, A. M.; Pinto-Costa, C.; Gomes, A. R.; Mamede,
In summary, in this work we demonstrated the potential
antitumor activity for levoglucosenone, a glucose-related